A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Metformin (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 20 Sep 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 20 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 24 Feb 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2023.